These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35644903)

  • 1. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
    Corrao MM; Nelson LA
    CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
    Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
    Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.
    Gao J; Li J; Lu X; Yang J
    Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1011-1016. PubMed ID: 36016507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
    Monahan C; McCoy L; Powell J; Gums JG
    Ann Pharmacother; 2022 Sep; 56(9):1049-1057. PubMed ID: 35040357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine/Samidorphan: First Approval.
    Paik J
    Drugs; 2021 Aug; 81(12):1431-1436. PubMed ID: 34304374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
    Faden J; Serdenes R; Citrome L
    Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
    Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.
    Cunningham JI; Eyerman DJ; Todtenkopf MS; Dean RL; Deaver DR; Sanchez C; Namchuk M
    J Psychopharmacol; 2019 Oct; 33(10):1303-1316. PubMed ID: 31294646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine and samidorphan combination treatment: A systematic review.
    Jawad MY; Alnefeesi Y; Lui LMW; Ceban F; Chen-Li DCJ; Teopiz K; Jaberi S; Gillissie ES; Vincenzo JDD; Rosenblat JD; McIntyre RS
    J Affect Disord; 2022 Mar; 301():99-106. PubMed ID: 35007644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
    Sun L; McDonnell D; von Moltke L
    Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating Schizophrenia and Bipolar I Disorder in the Real-World Setting: Effectiveness and Safety of Olanzapine/Samidorphan Combination.
    Price MZ; Price RL
    Prim Care Companion CNS Disord; 2024 Apr; 26(2):. PubMed ID: 38579267
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
    Kahn RS; Silverman BL; DiPetrillo L; Graham C; Jiang Y; Yin J; Simmons A; Bhupathi V; Yu B; Yagoda S; Hopkinson C; McDonnell D
    Schizophr Res; 2021 Jun; 232():45-53. PubMed ID: 34015555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine/Samidorphan: A New Option for the Treatment of Adults With Schizophrenia or Bipolar I Disorder.
    Pham H; Warlick H; Bermudez R; Nguyen Q; Rey JA
    J Pharm Technol; 2022 Oct; 38(5):304-313. PubMed ID: 36046346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study.
    Kahn RS; Kane JM; Correll CU; Arevalo C; Simmons A; Graham C; Yagoda S; Hu B; McDonnell D
    J Clin Psychiatry; 2023 Mar; 84(3):. PubMed ID: 36946605
    [No Abstract]   [Full Text] [Related]  

  • 16. Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.
    Sun L; Mills R; Sadler BM; Rege B
    J Clin Pharmacol; 2021 Nov; 61(11):1430-1441. PubMed ID: 34018607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.
    Srisurapanont M; Suttajit S; Likhitsathian S; Maneeton B; Maneeton N
    Sci Rep; 2021 Apr; 11(1):7583. PubMed ID: 33828206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo Characterization of the Opioid Receptor-Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations.
    Tan LA; Gajipara N; Sun L; Bacolod M; Zhou Y; Namchuk M; Cunningham JI
    Neuropsychiatr Dis Treat; 2022; 18():2497-2506. PubMed ID: 36345421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precipitated opioid withdrawal in a patient started on olanzapine/samidorphan.
    Chambers A; Patton J; Wills BK
    Am J Emerg Med; 2024 May; 79():230.e1-230.e2. PubMed ID: 38556414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine/samidorphan (Lybalvi) for schizophrenia and bipolar disorder.
    Med Lett Drugs Ther; 2021 Nov; 63(1638):191-192. PubMed ID: 35085217
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.